ES2338109T3 - Producto de combinacion de inhibidor de la familia src de las tirosina quinasas no receptoras y gemcitabina para uso en el tratamiento o profilaxa de cancer de pancreas. - Google Patents

Producto de combinacion de inhibidor de la familia src de las tirosina quinasas no receptoras y gemcitabina para uso en el tratamiento o profilaxa de cancer de pancreas. Download PDF

Info

Publication number
ES2338109T3
ES2338109T3 ES03772404T ES03772404T ES2338109T3 ES 2338109 T3 ES2338109 T3 ES 2338109T3 ES 03772404 T ES03772404 T ES 03772404T ES 03772404 T ES03772404 T ES 03772404T ES 2338109 T3 ES2338109 T3 ES 2338109T3
Authority
ES
Spain
Prior art keywords
chloro
mixture
quinazoline
ylamino
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03772404T
Other languages
English (en)
Spanish (es)
Inventor
Alan Barge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2338109T3 publication Critical patent/ES2338109T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Control And Other Processes For Unpacking Of Materials (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES03772404T 2002-11-13 2003-11-07 Producto de combinacion de inhibidor de la familia src de las tirosina quinasas no receptoras y gemcitabina para uso en el tratamiento o profilaxa de cancer de pancreas. Expired - Lifetime ES2338109T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0226434.9A GB0226434D0 (en) 2002-11-13 2002-11-13 Combination product
GB0226434 2002-11-13

Publications (1)

Publication Number Publication Date
ES2338109T3 true ES2338109T3 (es) 2010-05-04

Family

ID=9947715

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03772404T Expired - Lifetime ES2338109T3 (es) 2002-11-13 2003-11-07 Producto de combinacion de inhibidor de la familia src de las tirosina quinasas no receptoras y gemcitabina para uso en el tratamiento o profilaxa de cancer de pancreas.

Country Status (16)

Country Link
US (1) US20060142297A1 (OSRAM)
EP (1) EP1562612B1 (OSRAM)
JP (1) JP2006508953A (OSRAM)
KR (1) KR20050074573A (OSRAM)
CN (1) CN100467027C (OSRAM)
AT (1) ATE456370T1 (OSRAM)
AU (1) AU2003279456B2 (OSRAM)
BR (1) BR0316170A (OSRAM)
CA (1) CA2504666A1 (OSRAM)
DE (1) DE60331162D1 (OSRAM)
ES (1) ES2338109T3 (OSRAM)
GB (1) GB0226434D0 (OSRAM)
NO (1) NO20052312L (OSRAM)
NZ (1) NZ539514A (OSRAM)
WO (1) WO2004043472A1 (OSRAM)
ZA (1) ZA200503805B (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX242553B (es) 2000-10-20 2006-12-06 Eisai Co Ltd Derivados aromaticos que contienen nitrogeno.
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
NZ539408A (en) 2002-11-04 2007-09-28 Astrazeneca Ab Quinazoline derivatives as SRC tyrosine kinase inhibitors for treating solid tumours
WO2004080462A1 (ja) 2003-03-10 2004-09-23 Eisai Co., Ltd. c-Kitキナーゼ阻害剤
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
GB0412074D0 (en) 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
WO2006030826A1 (ja) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
GB0427697D0 (en) 2004-12-17 2005-01-19 Astrazeneca Ab Chemical process
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
AU2007252506C1 (en) 2006-05-18 2012-07-19 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
EP2065372B1 (en) 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
AU2008205847A1 (en) 2007-01-19 2008-07-24 Eisai R & D Management Co., Ltd. Composition for treatment of pancreatic cancer
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
AU2008325608B2 (en) 2007-11-09 2013-03-14 Eisai R & D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
KR101677790B1 (ko) 2010-06-25 2016-11-18 에자이 알앤드디 매니지먼트 가부시키가이샤 키나제 저해 작용을 갖는 화합물의 병용에 의한 항종양제
KR101762999B1 (ko) 2011-04-18 2017-07-28 에자이 알앤드디 매니지먼트 가부시키가이샤 종양 치료제
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
TWI577671B (zh) * 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
WO2013152313A1 (en) 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
CA2889866A1 (en) 2012-12-21 2014-06-26 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
HRP20221047T1 (hr) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
CA2978226C (en) 2015-03-04 2025-02-18 Eisai R&D Management Co., Ltd. COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER
US20170022576A1 (en) 2015-03-18 2017-01-26 The Regents Of The University Of California Compositions and methods for identifying anti-cancer, anti-metastatic and anti-stress agents
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
MX381976B (es) 2015-08-20 2025-03-13 Eisai R&D Man Co Ltd Agente terapéutico contra tumores.
KR102539920B1 (ko) 2017-02-08 2023-06-05 에자이 알앤드디 매니지먼트 가부시키가이샤 종양-치료용 약제학적 조성물
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
ID30046A (id) * 1998-09-25 2001-11-01 Warner Lambert Co Kemoterapi kanker dengan asetildinalina digabung dengan gemsitabina, kapestabina atau kisplatin
ATE253915T1 (de) * 1999-06-30 2003-11-15 Merck & Co Inc Src-kinase hemmende verbindungen
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
GB0101599D0 (en) * 2001-01-22 2001-03-07 Novartis Ag Organic compounds
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0412074D0 (en) * 2004-05-29 2004-06-30 Astrazeneca Ab Combination product

Also Published As

Publication number Publication date
EP1562612B1 (en) 2010-01-27
KR20050074573A (ko) 2005-07-18
BR0316170A (pt) 2005-09-27
NO20052312L (no) 2005-06-06
CN1711094A (zh) 2005-12-21
ZA200503805B (en) 2006-09-27
GB0226434D0 (en) 2002-12-18
NZ539514A (en) 2007-11-30
CA2504666A1 (en) 2004-05-27
CN100467027C (zh) 2009-03-11
DE60331162D1 (de) 2010-03-18
AU2003279456A1 (en) 2004-06-03
US20060142297A1 (en) 2006-06-29
JP2006508953A (ja) 2006-03-16
WO2004043472A1 (en) 2004-05-27
ATE456370T1 (de) 2010-02-15
AU2003279456B2 (en) 2007-05-17
EP1562612A1 (en) 2005-08-17

Similar Documents

Publication Publication Date Title
ES2338109T3 (es) Producto de combinacion de inhibidor de la familia src de las tirosina quinasas no receptoras y gemcitabina para uso en el tratamiento o profilaxa de cancer de pancreas.
ES2225545T3 (es) Derivados de quinazolina para el tratamiento de tumores.
US11377451B2 (en) Compositions and methods for treating cancer
ES2269769T3 (es) Terapia de combinacion ee comprende zd6474 y un taxano.
US20100029673A1 (en) Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use
RU2267489C2 (ru) Производные хиназолина, способ их получения и фармацевтическая композиция
ES2412879T3 (es) Tratamiento combinado del cáncer que comprende inhibidores de EGFR/HER2
ES2312557T3 (es) Derivados de quinazolina.
ES2272737T3 (es) Derivados de quinolina y su uso como inhibidores de tirosina quinasas.
ES2762641T3 (es) Inhibidores de proteína quinasa de 2-aminopiridina sustituida con piridina
US20070207996A1 (en) Novel Compositions And Methods Of Treatment
ES3042620T3 (en) Antitumor-effect enhancer using pyrazolo[3,4-d]pyrimidine compound
ES2300619T3 (es) Derivados de quinolina como inhibidores de src tirosina quinasa.
US12115152B2 (en) Pan-RAF kinase inhibitor and use thereof
MXPA05005119A (es) Producto de combinacion de inhibidor de la familia src de cinasas de tirosina de no receptor y gemcitabina.
ES2364030T3 (es) Terapia de combinación de zd6474 con 5-fu y/o cpt-11.
KR20250099146A (ko) Prmt5 저해제와 dna 손상 유도 물질의 약학적 조합물
Coyne et al. Role of HSP90 Inhibitors in the Treatment
CN101437810A (zh) 喹唑啉衍生物
WO2018106118A1 (en) Treatment of diffuse intrinsic pontine glioma
JP2014091711A (ja) Ｈｓｐ９０阻害剤と抗腫瘍性白金錯体との組み合わせ